AZ
Arizona Senate Bill SB1460

Arizona 2025 Regular Session

Arizona Senate Bill SB1460

Introduced
2/4/25  
Report Pass
2/19/25  
Report Pass
2/25/25  
Report Pass
3/3/25  

Caption

Appropriation; midomafetamine; research

Impact

The bill seeks to facilitate significant advancements in PTSD treatment by enabling the awarding of grants to entities that have met specific criteria, including having completed a late-stage clinical trial and currently participating in the FDA drug review process. This support is expected to contribute to the broader discourse on mental health treatment options in Arizona and may pave the way for the eventual approval and use of midomafetamine as a therapy for PTSD, thus impacting health policy within the state.

Summary

Senate Bill 1460 proposes an appropriation of $10,000,000 from the state general fund for the fiscal year 2025-2026 to support the Department of Health Services in funding research and clinical trials related to midomafetamine, specifically for treating post-traumatic stress disorder (PTSD). This financial allocation is aimed at advancing the state's initiative to enhance mental health treatment options and support ongoing clinical trials that are crucial for establishing the efficacy of the drug in this area.

Sentiment

The sentiment surrounding SB1460 appears to be positive, as it is viewed as a proactive measure to address the pressing issue of PTSD and improve healthcare services within the state. Supporters of the bill see the funding as a critical step towards developing potentially effective treatments for mental health conditions, which have significant social implications. The bipartisan support indicated in the voting history reflects a shared recognition of the importance of mental health research.

Contention

While the bill has garnered support, potential points of contention could arise from budgetary considerations and priorities. Critics may voice concerns regarding the allocation of funds towards a single drug's research instead of broader mental health initiatives. Moreover, discussions may surface about the efficacy and safety of midomafetamine, necessitating a thorough evaluation of its clinical outcomes. As stakeholders debate these points, the bill may also face scrutiny regarding the management of state funds and the legislative approach to healthcare funding.

Latest SB1460 Activity

Companion Bills

No companion bills found.

Similar Bills

MD SB360

Budget Bill (Fiscal Year 2025)

MD HB350

Budget Bill (Fiscal Year 2025)

MD SB181

Budget Bill (Fiscal Year 2024)

MD HB200

Budget Bill (Fiscal Year 2024)

PA HB611

To provide appropriations from the General Fund for the expenses of the Executive, Legislative and Judicial Departments of the Commonwealth, the public debt and the public schools for the fiscal year July 1, 2023, to June 30, 2024, and for the payment of bills incurred and remaining unpaid at the close of the fiscal year ending June 30, 2023; to provide appropriations from special funds and accounts to the Executive and Judicial Departments for the fiscal year July 1, 2023, to June 30, 2024, and for the payment of bills remaining unpaid at the close of the fiscal year ending June 30, 2023; to provide for the appropriation of Federal funds to the Executive and Judicial Departments for the fiscal year July 1, 2023, to June 30, 2024, and for the payment of bills remaining unpaid at the close of the fiscal year ending June 30, 2023; and to provide for the additional appropriation of Federal and State funds to the Executive and Legislative Departments for the fiscal year July 1, 2022, to June 30, 2023, and for the payment of bills incurred and remaining unpaid at the close of the fiscal year ending June 30, 2022.

MD HB350

Budget Bill (Fiscal Year 2026)

MD SB319

Budget Bill (Fiscal Year 2026)

MD HB300

Budget Bill (Fiscal Year 2023)